Abstract
LETTER TO THE EDITOR Pay-for-performance Versus a Budget-Restrictive System for the Management of Dyslipidemia. Should this Approach also be Applied in Hypertension?
Highlights
Pay-for-performance Versus a Budget-Restrictive System for the Management of Dyslipidemia
The results of the Dyslipidemia International Study (DYSIS) were reported yesterday in the European Society of Cardiology (ESC) congress held at Amsterdam, Netherlands [1]
A total of 85% of German patients were treated with simvastatin compared with just 66% of UK patients, while nearly 25% of UK patients were treated with atorvastatin vs. just
Summary
Pay-for-performance Versus a Budget-Restrictive System for the Management of Dyslipidemia. It seems that lipid targets are more likely to be achieved in clinical practice in pay-for-performance than in budget-restrictive systems, like in Germany [1]. These despite the fact that the German population had a higher baseline incidence of cerebrovascular disease, peripheral arterial disease and diabetes mellitus; more secondary prevention patients that should achieve even lower LDL-C targets.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
